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Summary
BACKGROUND: To date, comprehensive data on drug
utilisation in Swiss nursing homes are lacking.
OBJECTIVE: To describe drug prescription patterns,
polypharmacy and potentially inappropriate medication
(PIM) in Swiss nursing home residents (NHR).
METHODS: Using administrative claims data provided by
the Swiss health insurance company Helsana, we as-
sessed drug claims and drug costs in 2016 in individuals
aged ≥65 years and insured with Helsana, who were either
NHR or living in the community (reference group, RG). In
particular, we analysed the prevalence of polypharmacy
(≥5 claims for different drugs during a 3-month period)
and PIM use according to the 2015 Beers criteria and the
PRISCUS list. We standardised the results to the Swiss
population.
RESULTS: In 2016, NHR had on average nearly twice
as many drug claims per capita as individuals in the RG
(NHR 58.8; RG 30.8). The average per capita drug costs
per day for NHR were low, but higher than in the RG (NHR
CHF 8.55; RG CHF 5.45). The same pattern applied to
the prevalence of polypharmacy (NHR 85.5%; RG 50.4%).
Standardisation by age and sex did not materially alter
these observations. Overall, 79.1% of NHR received ≥1
PIM, and 56.2% were long-term users (≥3 claims) of at
least one PIM (based on the combined PRISCUS list and
Beers criteria). Among all PIMs in nursing homes, quetiap-
ine (antipsychotic agent), lorazepam (anxiolytic agent) and
zolpidem (hypnotic agent) were the most prevalent (22.4,
20.2 and 13.0%, respectively).
CONCLUSIONS: The high prevalence of polypharmacy
and PIM in Swiss nursing homes may indicate a need for
interventions aiming at de-prescribing drugs with an un-
favourable benefit-risk profile.
Keywords: Drug utilisation, polypharmacy, potentially in-
appropriate medication, nursing home, claims data, Hel-
sana, Switzerland, descriptive study
Introduction
In most high-income countries, the number of nursing
home residents (NHR) is increasing. On average, 13% of
Europeans aged over 65 years receive long-term care. Be-
tween-country variation is high, with the proportion of el-
derly long-term care receivers (not necessarily institution-
alised) ranging from 2% in Portugal to more than 20% in
Switzerland [1], where people aged 65 years or older ac-
counted for 18.1% of the total population in 2016. It has
been estimated that this proportion will further increase to
26% by 2045 [2]. Up to 91% of NHR regularly consume
five or more medications [3]. Multimorbid individuals are
the rule rather than the exception, which often leads to
complex medication regimens and excessive polypharma-
cy [4]. The term polypharmacy refers to the concurrent use
of multiple medications, especially if the medications are
unnecessarily numerous or complex [5]. In a review by
Morin et al., the total number of prescribed medications
was reported to be the main driving factor for potentially
inappropriate medication (PIM) use [6]. Medications are
considered potentially inappropriate for use in the elderly
if the risk of adverse events exceeds either the expected
benefit, or when a better-tolerated or safer alternative is
available [7]. PIM use has been found to be associated with
an increased risk of poor health outcomes, including falls,
confusion and mortality [8]. Furthermore, prescription of
additional drugs to treat drug-induced symptoms can lead
to prescribing cascades; this can occur when an adverse
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drug reaction is misinterpreted as a new medical problem
[9]. Since the first related initiative of Beers et al. in 1991
in the USA [10], several tools to identify PIM have been
developed. A recent review reported a prevalence of PIM
in NHR between 18.5 and 82.6% in 17 studies on the ba-
sis of the Beers criteria [11]. Several countries established
lists adapted to their local contexts; these include Canada
[12], France [13], Germany (the PRISCUS list) [14] and
seven EU countries in a combined approach (EU(7)-PIM
list) [15].
Although polypharmacy and PIM are different concepts,
they are strongly associated [16]. A recently published re-
view found an increased risk of all-cause hospitalisation
for NHR when exposed to polypharmacy and PIM [17].
Hospitalisations from nursing homes are associated with
negative outcomes for residents and a substantial economic
burden, with a relevant part thereof being preventable [17,
18]. Moreover, age-related physiological changes increase
the risk of drug-related adverse events in the elderly [19].
Since drug prescribing plays a major role in nursing home
settings, its optimisation has become a public-health issue
worldwide [7]. Despite serious concerns about inappropri-
ate drug prescribing and polypharmacy, only few studies
have analysed medication utilisation in the elderly Swiss
population [20–22]. To date, no comprehensive descriptive
data on prescription patterns in Swiss nursing homes have
been available. In the present study, we therefore aimed to
analyse drug prescription patterns and to assess the preva-
lence of polypharmacy and use of PIM in Swiss NHR
based on administrative claims data provided by the Swiss
health insurance company Helsana.
Methods
Study design and data source
We conducted a retrospective descriptive analysis of health
insurance claims data covering the year 2016. The analysis
was based on the electronic administrative claims database
of the Swiss health insurance company Helsana.
All persons residing in Switzerland are required to pur-
chase mandatory health insurance (with a very broad ben-
efit package). Health insurers must in return offer manda-
tory insurance to everyone, irrespective of age or health
status. Although insurance companies are private and there
is no uniform national health insurance system, conditions
and benefit packages are uniform across different
providers. Federal authorities closely regulate the market.
The Helsana group is one of the largest health insurers
in Switzerland, providing mandatory health insurance to
some 1.17 million individuals from all 26 cantons (year
2016). Helsana’s administrative claims data cover almost
all healthcare invoices and are thus highly reliable. Record-
ed variables cover demographics, postal codes and claims
sent to Helsana for reimbursement. The latter include drug
prescriptions (including dose, galenic form and pack size),
medical treatments and diagnostic tests. For the purpose
of this analysis, one drug claim refers to the purchase of
one single drug package; if several drugs were bought on
a single occasion, these were treated as separate claims.
Drugs were coded according to the Anatomical Therapeu-
tic Chemical (ATC) classification system, which allows
drug classes and individual active agents to be uniquely
identified. However, data do not encompass insured per-
sons’ personal characteristics such as smoking habits, alco-
hol consumption or weight / body mass index. Moreover,
they do not cover symptoms, test results, outpatient diag-
noses or medical resource use during acute hospitalisation.
Thus, inpatient drug prescriptions are not available in the
data, whereas outpatient drug prescriptions and most nurs-
ing home drug prescriptions (see below) are recorded.
We were granted access to anonymised datasets (from the
database located at Helsana) covering the patient informa-
tion and parameters relevant for this analysis.
Study population
In the Helsana database, we identified all NHR aged 65
years or older in 2016 who received at least one prescribed
drug coded in the ATC classification system (99.8% of all
NHR) and who had a minimum stay of 28 days in a nursing
home (in order to focus on long-term institutionalised pa-
tients only). We then excluded all NHR whose invoices for
nursing home care were based on lump sums, as in these
cases drug utilisation was not detailed in the database (this
affected, in particular, all NHR of the cantons Fribourg and
Ticino).
To enable a comparison between NHR and the general el-
derly Swiss population, we identified a reference group
(RG) consisting of all individuals aged 65 years or older
insured with Helsana in 2016 who did not live in a nursing
home and who had at least one claim of a prescribed drug
coded in the ATC classification system.
Definitions
Polypharmacy
Referring to existing literature [23], we defined polyphar-
macy as the concurrent use of ≥5 different prescribed drugs
(according to their ATC code). Where a claim was present,
we assumed it to indicate the use of the respective drug.
Potentially inappropriate medication
We used the 2015 Beers criteria and the PRISCUS list
(2011) [8, 14] to identify PIM. Since the Beers criteria are
of American origin and the PRISCUS list was adapted to
the German market, our analyses considered only drugs li-
censed in Switzerland. We a priori defined long-term use
of PIM as ≥3 claims of the same PIM in 2016 based on
the assumption that one or a maximum of two claims of
the same drug can be seen as short-term use for a defined
time and diagnosis, whereas three or more separate claims
of the same drug indicate regular use.
Statistical analysis
We assessed characteristics of the study population (such
as sex and average age), the number of drug claims (overall
and average per capita) including ATC codes and drug
costs (overall and average per capita per day) in 2016 both
in NHR and in the RG, and stratified our analyses by sex,
age and canton of residence. We used means, standard de-
viations (SDs) and 95% confidence intervals (CIs) for de-
scriptive statistics. Selected key parameters were standard-
ised by 5-year age groups and sex to prevent confounding
owing to different age or sex structures in NHR and the
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RG, using the Swiss population aged 65 and older as the
standard population [24].
To estimate the number of different drugs taken concur-
rently and thus the prevalence of polypharmacy, we con-
sidered only drug claims in the second quarter of 2016.
A 3-month time period was chosen to make a concurrent
(rather than subsequent) use of the prescribed medications
likely. A study based on Danish prescription data estimated
that 80% of individuals who had purchased five or more
drugs (excluding topical preparations and antineoplastic
drugs) during 3 months were subject to an episode of
polypharmacy (defined as the concurrent use of five or
more drugs) at least once during the year [25]. We specif-
ically chose the second quarter of the year as it is less
susceptible to seasonal diseases (such as influenza). Ex-
clusively in the polypharmacy analysis, we also included
individuals who had no history of prescribed drugs in the
respective period to achieve an overall estimate of the
mean number of different concurrent drugs per person for
the population of interest. In a sub-analysis, we excluded
ATC codes representing topical drugs (e.g., galenic forms
such as creams, ointments, gels, lotions, nasal sprays,
aerosols or eye drops) to analyse systemic drugs only.
To identify explicit PIM in the dataset (independent of di-
agnoses or conditions), we created three separate lists of
ATC codes (2015 Beers criteria; PRISCUS list; combina-
tion of both). We calculated prevalence of PIM use in NHR
according to the number of claims (≥1 claim or ≥3 claims
of the same PIM) and stratified the results by age, sex, can-
ton of residence and set of criteria used.
To enable statements on a Swiss population level, we ex-
trapolated all results according to age, sex and canton of
residence using yearly published census data from the
Swiss Federal Office for Statistics balancing out slight de-
viations of the structure of the Helsana population from
that of the general Swiss population [26].
We used SAS 9.4 software (SAS Institute, Cary, NC) for
the analyses.
Results
Characteristics of the study population, number of
drug supplies, and drug costs
We analysed claims data from a total of 91,166 NHR and
1,364,755 individuals in the RG (extrapolated). Table 1
summarises the characteristics of the study population, in-
cluding drug claims and drug costs in 2016.
The average age was markedly higher in NHR than in the
RG (NHR 85.7 years; RG 75.0 years). The same was true
for the proportion of females (NHR 71.9%; RG 55.0%).
Over the 1-year observation period, irrespective of sex and
across all age groups, NHR received on average nearly
twice as many drug claims per capita as individuals in the
RG (NHR 58.8; RG 30.8; NHR standardised by age and
sex [sNHR] 64.6; RG standardised by age and sex [sRG]
31.1). Moreover, the average per capita drug costs per day
of NHR were substantially higher compared with the RG
(NHR CHF 8.55; RG CHF 5.45; sNHR CHF 11.45; sRG
CHF 5.45).
In NHR, the average number of per capita drug claims was
lower in men than in women, but men’s average per capi-
ta drug costs per day were higher (men CHF 9.45; women
CHF 8.20). Standardised by age, this difference became
relatively small (men CHF 11.60; women CHF 11.30). In
the RG, we found the same pattern (table 1).
Table 1: Characteristics of Swiss NHR and the RG (individuals aged ≥65 years insured with Helsana, excluding NHR) including drug claims and drug costs, year 2016.
NHR RG
Sex, n (%)
Total 91,166 (100.0) 1,364,755 (100.0)
Female 65,514 (71.9) 750,540 (55.0)
Male 25,652 (28.1) 614,215 (45.0)
Average age in years (SD)
Total 85.7 (17.4) 75.0 (17.7)
Female 86.6 (16.3) 75.5 (17.9)
Male 83.6 (19.2) 74.5 (17.5)
Number of overall drug claims in thousand (%)
Total 5360.2 (100.0) 42,100.0 (100.0)
Female 3915.4 (73.0) 24,142.9 (57.3)
Male 1444.7 (27.0) 17,957.1 (42.7)
Overall drug costs in million CHF (%)
Total 210.4 (100.0) 2711.9 (100.0)
Female 149.0 (70.8) 1406.9 (51.9)
Male 61.4 (29.2) 1305.0 (48.1)
Average per capita drug claims (SD) [standardised by age and sex*]
Total 58.8 (48.2) [64.3 (48.6)] 30.8 (29.1) [31.1 (29.1)]
Female 59.8 (47.6) [66.2 (48.1)] 32.2 (29.6) [32.4 (29.6)]
Male 56.3 (49.8) [62.1 (50.3)] 29.2 (28.3) [29.4 (28.3)]
Average per capita drug costs per day (CHF) (SD) [standardised by age and sex*]
Total 8.55 (13.65) [11.45 (13.80)] 5.45 (13.85) [5.45 (13.85)]
Female 8.20 (13.00) [11.30 (13.25)] 5.15 (12.75) [5.15 (12.75)]
Male 9.45 (15.30) [11.60 (15.35)] 5.80 (15.25) [5.85 (15.25)]
NHR = nursing home residents; RG = reference group; SD = standard deviation * The overall results for NHR and the RG are standardised by age and sex, while the results for
females and males are standardised by age
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We observed a noticeable decrease of average per capita
drug costs per day in NHR with advancing age (fig. 1).
Costs decreased from over CHF 13.00 in 70- to 74-year-
olds to below CHF 6.00 in residents aged 95 years and old-
er. The RG, in contrast, showed maximum per capita costs
per day of CHF 6.00 in individuals aged 80 to 84 years and
minimum costs of CHF 4.15 in individuals aged 95 and
older.
Figure 2 illustrates the relative deviation of the average per
capita drug costs per day in nursing homes for each can-
ton of Switzerland compared with the Swiss average value
(CHF 8.55). The costs were highest in the canton Basel-
Stadt at CHF 10.20 (+19.3%), and lowest in the canton Ap-
penzell Ausserrhoden with CHF 5.85 (−31.6%). The ob-
served cantonal pattern was similar in the RG (data not
shown).
Polypharmacy
Table 2 characterises the prevalence of polypharmacy and
the number of different concurrent drugs per person in
NHR and the RG. Overall, polypharmacy was present in
85.5% of all NHR (sNHR 85.1%). In contrast, prevalence
of polypharmacy was markedly lower in the RG (50.4%;
sRG 50.5%). Whereas the prevalence of polypharmacy
among NHR showed little variation across different age
categories with minimum and maximum values of 81.4%
(65- to 69-year-olds) and 87.0% (70- to 79-year-olds), re-
spectively, it varied in the RG from a minimum of 39.8%
among individuals aged 65 to 69 to a maximum of 63.5%
among those aged 85 to 89 years.
In NHR and the RG, the average number of different drugs
per person taken concurrently amounted to 9.4 (sNHR 9.9)
and 5.5 (sRG 5.6), respectively (second quarter of 2016).
In both groups, women received on average slightly more
concurrent drugs than men (table 2). In NHR, we observed
9.6 drugs in 65- to 69-year-olds, a maximum of 10.5 drugs
in 70- to 74-year-olds, and 8.5 drugs in the over 95-year-
olds. In the RG, a minimum number of 4.6 and a maximum
number of 6.7 different concurrently used drugs was found
in 65- to 69-year-olds and 85- to 89-year-olds, respectively.
In individuals aged 95 years and older, the average number
of drugs amounted to 6.0 (fig. 3).
In the subanalysis including systemic drugs only, the over-
all prevalence of polypharmacy remained high at 78.7 and
43.0% in NHR and the RG, respectively (sNHR 80.0
[80.0%]; sRG 43.0 [43.0%]). Accordingly, the average
number of different concurrent drugs per person did not
decrease substantially (NHR 8.0; RG 4.6; sNHR 8.5; sRG
4.6), indicating a predominant use of systemic drugs both
in NHR and in the RG.
Prescribed agents and PIM
Table 3 shows the 15 most frequent active agents in nurs-
ing homes in 2016, by decreasing number of claims. Of
these 15 agents, the majority were analgesics (ATC code
starting with N02) and psycholeptics (ATC code starting
with N05). Each of the 15 drugs was prescribed to a higher
proportion of NHR than persons in the RG; 10 out of 15
drugs were prescribed to more than a quarter of all NHR.
In particular, every second NHR received at least one pre-
scription of paracetamol. A total of 22.4 and 11.2% of
NHR received at least one prescription of quetiapine and
fentanyl, respectively, whereas the same applied to only
1.7 and 1.1% of the RG. The corresponding analysis for the
RG is shown in supplementary table S1 in appendix 1.
Overall, 79.1% of NHR received at least one PIM when
considering both the PRISCUS list and the 2015 updated
Beers criteria (59.5% according to the PRISCUS list alone
and 74.0% according to Beers criteria alone). Based on the
PRISCUS list and Beers criteria combined, 56.2% of all
Figure 1: Average per capita drug costs per day in different age groups for NHR and the RG (individuals aged ≥65 years insured with Hel-
sana, excluding NHR) with 95% confidence intervals, year 2016.NHR = nursing home residents; RG = reference group
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NHR were long-term users (≥3 claims) of at least one PIM
(40.9% according to the PRISCUS list alone and 51.3% ac-
cording to Beers criteria alone). Prevalence of long-term
PIM prescription was highest in NHR aged 70 to 74 years
and decreased thereafter, irrespective of the tool used to
identify PIM (supplementary fig. S1 in appendix 1).
Table 4 displays the 15 most prevalent PIMs among NHR.
Psycholeptics were the most frequently prescribed PIM
group including quetiapine, lorazepam, zolpidem, risperi-
done, pipamperone, haloperidol, oxazepam and hydrox-
yzine.
Overall prevalence of PIM use was higher among female
NHR than male NHR (women: 80.2%; men: 76.3%) (table
S2 in appendix 1). Whereas a higher proportion of female
NHR had one or more claims of benzodiazepines and relat-
ed drugs (e.g., lorazepam, oxazepam and zolpidem), con-
siderably more male NHR were prescribed paraffin oil (a
Figure 2: Relative deviation of per capita costs per day for drug claims in Swiss nursing homes compared with the Swiss average value of
CHF 8.55, year 2016.FR, TI: not applicable (invoices for nursing care based on lump sums)AG = Aargau; AI = Appenzell Innerrhoden; AR =
Appenzell Ausserrhoden; BE = Bern; BL = Basel-Landschaft; BS = Basel-Stadt; FR = Freiburg; GE = Genf; GL = Glarus; GR = Graubünden;
JU = Jura; LU = Luzern; NE = Neuenburg; NW = Nidwalden; OW = Obwalden; SG = St. Gallen; SH = Schaffhausen; SO = Solothurn; SZ =
Schwyz; TG = Thurgau; TI = Tessin; UR = Uri; VD = Waadt; VS = Wallis; ZG = Zug; ZH = Zürich
Table 2: Prevalence of polypharmacy and number of different concurrent drugs per person in NHR and the RG (individuals aged ≥65 years insured with Helsana, excluding
NHR), 2nd quarter of 2016.
NHR RG
Total
(n = 74,290)
Female
(n = 54,278)
Male
(n = 20,012)
Total
(n = 1,364,755)
Female
(n = 750,540)
Male
(n = 614,215)
Prevalence of polypharmacy, % (95% CI) [standardised by age and sex*]
85.5 (84.9–86.1) 85.8 (85.1–86.5) 84.7 (83.5–86.0) 50.4 (50.2–50.7) 52.4 (52.1–52.7) 48.1 (47.8–48.4)
[85.1 (84.4–85.8)] [85.9 (85.1–86.7)] [84.0 (82.7–85.3)] [50.5 (50.2–50.8)] [52.3 (51.9–52.7)] [48.2 (47.8–48.6)]
Mean number of different concurrent drugs per individual, n (SD) [standardised by age and sex*]
9.4 (11.3) 9.5 (11.1) 9.3 (11.8) 5.5 (11.6) 5.8 (11.6) 5.3 (11.6)
[9.9 (13.1)] [10.1 (13.0)] [9.7 (9.7)] [5.6 (11.5)] [5.8 (11.5)] [5.3 (11.5)]
Number of individuals, categorised by the number of concurrent different drugs, n (%)
0 0 (0.0) 0 (0.0) 0 (0.0) 156,348 (11.5) 79,264 (10.6) 77,084 (12.6)
1–3 6605 (8.9) 4704 (8.7) 1902 (9.5) 392,873 (28.8) 209,162 (27.9) 183,711 (29.9)
4–6 15,615 (21.0) 11,247 (20.7) 4368 (21.8) 350,565 (25.7) 191,447 (25.5) 159,118 (25.9)
7–9 19,227 (25.9) 14,082 (25.9) 5145 (25.7) 223,114 (16.3) 127,289 (17.0) 95,825 (15.6)
10–12 15,180 (20.4) 11,294 (20.8) 3886 (19.4) 123,324 (9.0) 72,409 (9.6) 50,915 (8.3)
13–15 9457 (12.7) 7008 (12.9) 2449 (12.2) 61,847 (4.5) 37,272 (5.0) 24,575 (4.0)
>15 8207 (11.0) 5943 (10.9) 2263 (11.3) 56,684 (4.2) 33,697 (4.5) 22,987 (3.7)
CI = confidence interval; NHR = nursing home residents; RG = reference group; SD = standard deviation * The overall results for NHR and the RG are standardised by age and
sex, while the results for females and males are standardised by age
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laxative) or belladonna alkaloids and derivatives (antispas-
modic agents).
Stratified by canton, we did not observe a clear pattern
regarding prevalence of PIM (table S3 in appendix 1).
Whereas the canton of Nidwalden showed a maximum val-
ue of 87.6%, only 67.2% of NHR in the neighbouring can-
ton of Obwalden (both rather rural areas) had at least one
claim of a PIM (PRISCUS list and Beers criteria com-
bined). In total, 15 and 21 out of 24 analysed cantons de-
viated less than 5 and 10%, respectively, from the average
PIM prevalence.
Discussion
To our knowledge, the present study is the first systematic
descriptive analysis of drug utilisation in Swiss nursing
homes. The study is based on claims data of a large
provider of Swiss mandatory health insurance; it includes
elderly patients from all parts of the country who were ei-
ther NHR or living in the community. Our results suggest
that per capita drug claims, average per capita drug costs
and the prevalence of polypharmacy were substantially
higher in NHR than in the RG. Standardisation by age and
sex did not materially alter these observations. Moreover,
we identified a considerable amount of PIM use in elderly
Swiss NHR.
The great majority (85.5%) of NHR were prescribed five
or more different drugs at the same time. A recent study
among NHR in Germany reported a similarly high preva-
lence of polypharmacy (83.5%) [27]. According to another
study based on Helsana claims data, 41.2% of the Swiss
general population aged 65 years or older (not living in
nursing homes) were exposed to polypharmacy between
2008 and 2010 [20]. The prevalence of polypharmacy of
Figure 3: Average number of different concurrent drugs per person with 95% confidence intervals across different age groups in NHR and the
RG (individuals aged ≥65 years insured with Helsana, excluding NHR), 2nd quarter of 2016.NHR = nursing home residents; RG = reference
group
Table 3: The 15 most frequent drugs in NHR compared with the RG (individuals aged ≥65 years insured with Helsana, excluding NHR) and the prevalence of their use, ranked
by number of drug claims, year 2016.
Active agent ATC code Number of drug
claims in NHR
Rank Number of drug
claims in RG
Rank Prevalence of use in
NHR (%)
Prevalence of use in
the RG (%)
Paracetamol N02BE01 260,211 1 1,202,864 2 54.4 34.6
Metamizole N02BB02 161,887 2 506,310 13 32.0 14.0
Torasemide C03CA04 143,192 3 511,161 12 38.3 11.7
Quetiapine N05AH04 136,026 4 106,810 85 22.4 1.7
Pantoprazole A02BC02 130,073 5 963,136 4 35.6 26.3
Macrogol A06AD65 129,455 6 318,776 22 32.2 12.6
Cholecalciferol A11CC05 128,905 7 640,780 7 32.0 17.8
Fentanyl N02AB03 110,441 8 105,330 88 11.2 1.1
Artificial tear fluid S01XA20 106,754 9 932,207 5 22.7 22.1
Diclofenac (topical) M02AA15 94,657 10 552,445 10 30.0 16.7
Acetylsalicylic acid B01AC06 93,777 11 1,220,562 1 32.1 29.4
Calcium + vitamin D A12AX 84,489 12 614,066 8 25.7 17.6
Urea D02AE01 74,255 13 232,686 34 25.3 7.5
Lorazepam N05BA06 72,715 14 427,467 15 19.9 7.9
Zolpidem N05CF02 72,538 15 588,007 9 13.0 8.4
ATC = Anatomical Therapeutic Chemical classification system; NHR = nursing home residents; RG = reference group
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50.4% in our RG thus may suggest a trend towards an
increasing number of individuals receiving polypharmacy
over time.
Consistent with the latter study [20], we observed a de-
crease in the number of different drugs taken concurrently
with increasing age. The reasons for this might be a de-
prescribing of unnecessary medications (medications aim-
ing mainly at a prolonged life expectancy rather than an
improved quality of life), especially in very frail and old
persons. In elderly patients, drug therapy in accordance
with guidelines is often neither effective nor feasible due
to different treatment approaches, possible drug-drug in-
teractions and necessary dose adjustments [28]. To curb
polypharmacy, clarifying and prioritising the diagnoses
that do (not) require therapy is thus essential [29]. Cooper
et al. reported that polypharmacy and associated adverse
drug events could be minimised by reducing the use of
nonessential (and potentially inappropriate) medications
and by reinforcing adherence of NHR [30].
Eight out of ten NHR in our study population received at
least one PIM when both the PRISCUS list and 2015 up-
dated Beers criteria were taken into account. Furthermore,
despite being considered PIMs, the psycholeptics quetiap-
ine, lorazepam and zolpidem were found among the 15
most frequently prescribed drugs in nursing homes. Psy-
choleptics increase the risk of cerebrovascular events as
well as the rate of cognitive decline and mortality in per-
sons with dementia [8].
One in ten NHR received paraffin oil, making it the fourth
most frequently used PIM among NHR. Viscous paraffin
is usually indicated for the short-term treatment of consti-
pation. In elderly people at risk of aspiration, side effects
such as lipid pneumonia occur more frequently [8].
Two systematic reviews also emphasised the substantial
occurrence of PIM in NHR: Storms et al. delineated a PIM
prevalence in nursing homes between 18.5 and 82.6% ac-
cording to Beers criteria [11]; Morin et al. described point
prevalences of PIM use (varying criteria to identify PIM)
ranging from 5.4 to 95%, with higher estimates reported in
Europe than in other continents, and in studies conducted
after 2005 compared with studies conducted between 1990
and 1999 [6].
Several limitations need to be considered when interpret-
ing the results of the present study. Our analyses relied
on healthcare invoices submitted to Helsana for reimburse-
ment by mandatory health insurance. Consequently, we
may have missed a number of drugs, in particular (1) non-
prescription drugs purchased over-the-counter, (2) drugs
paid for out-of-pocket by individuals whose healthcare ex-
penses principally eligible for reimbursement by the
mandatory health insurance did not exceed the annual de-
ductible, (3) drugs not listed for reimbursement in the
mandatory health insurance package, and (4) inpatient
drug prescriptions. According to internal analyses by
Swiss health insurers, the proportion of healthcare expens-
es below the annual deductible amounts to 2 to 3% of in-
voices [21]. Therefore, the drug utilisation reflected in our
claims data may be a slight underestimation, whereas a po-
tential selection bias is likely to be minor. Medications list-
ed for reimbursement in the mandatory health insurance
package account for 80% of the total medication costs in
Switzerland [21]. Prevalence of polypharmacy might thus
be underestimated to some extent. However, since all PIMs
licensed in Switzerland are listed for reimbursement, it is
very unlikely that we markedly underestimated their preva-
lence. Based on the lack of a universally used definition of
“long-term use”, we defined long-term PIM use as three or
more drug claims of the same PIM, assuming this defini-
tion to indicate a regular use. Therefore, a limited degree
of misclassification may be expected. Furthermore, we had
no information on whether the patients had actually taken
the dispensed drugs, as adherence is not guaranteed solely
by the purchase of a drug.
Table 4: The 15 most frequent PIM and the prevalence of their use in NHR according to the 2015 Beers criteria and PRISCUS list [8, 14], ranked by total number of recipients,
year 2016.
Rank PIM active agent ATC code List: Beers (B)
or PRISCUS
(P)
No of NHR with claim Prevalence of use
in NHR (%)
No of NHR with
long-term use (≥3
claims of same PIM)
Prevalence of long-
term use in NHR (≥3
claims of same PIM)
(%)
1 Quetiapine N05AH04 B 20,384 22.4 13,888 15.2
2 Lorazepam N05BA06 B/P 18,378 20.2 8091 8.9
3 Zolpidem N05CF02 B/P 11,807 13.0 7794 8.5
4 Paraffin oil A06AA01 P 8760 9.6 5457 6.0
5 Risperidone N05AX08 B 8749 9.6 6220 6.8
6 Pipamperone N05AD05 B 7810 8.6 4563 5.0
7 Haloperidol N05AD01 B/P 7213 7.9 2620 2.9
8 Ibuprofen M01AE01 B 6780 7.4 2205 2.4
9 Oxazepam N05BA04 B/P 5948 6.5 3844 4.2
10 Metoclopramide A03FA01 B 5397 5.9 1602 1.8
11 Belladonna alkaloids* A03B B 4613 5.1 585 0.6
12 Diclofenac p.o. M01AB05 B 3965 4.3 1275 1.4
13 Nitrofurantoin J01XE01 B/P 3731 4.1 614 0.7
14 Estriol G03CA04 B 2807 3.1 1156 1.3
15 Hydroxyzine N05BB01 B/P 2784 3.0 1981 2.2
Total PIM Beers and PRISCUS B/P 72,106 79.1 51,232 56.2
Total PIM Beers B 67,490 74.0 46,798 51.3
Total PIM PRISCUS P 54,253 59.5 37,268 40.9
ATC = Anatomical Therapeutic Chemical classification system; NHR = nursing home residents; No = number; PIM = potentially inappropriate medication; p.o. = peroral * Including
derivatives such as butylscopolamine (antispasmodic agent)
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The present study was based on the 2015 updated Beers
criteria and the PRISCUS list, both of which are widely
accepted and evidence-based tools to identify PIM. Un-
doubtedly, these lists are not meant to override either the
clinical judgment of the physician or an individual’s pref-
erence, values and needs [8]. Therefore, drugs identified
as PIMs may be appropriate in individual clinical situa-
tions, under special monitoring and at an appropriate age-
adjusted dose. Additionally, evidence of a significant asso-
ciation between PIM defined by Beers criteria and patient
outcomes, such as adverse drug events or quality of life,
is inconsistent [31, 32]. In contrast, PIMs defined by the
START/STOPP criteria, another tool to identify PIM, have
been shown to be significantly associated with adverse
drug events and hospitalisation [33, 34]. However, the in-
appropriateness of drugs defined by STOPP is usually
linked to exceeding a certain dosage or duration of use, a
diagnosis, a co-medication, a duplication of drug classes
or lack of an indication. Since required additional informa-
tion such as outpatient diagnoses, kidney function or cu-
mulative dosage was not captured in our data, we could not
analyse implicit PIM (drugs being inappropriate in individ-
ual, specific clinical situations, or above a certain single/
daily dose). The present study cannot, therefore, allow in-
ferences about the appropriateness of prescriptions and the
extent of overuse, underuse or misuse of medications on an
individual level. Nevertheless, the prevalence of PIM, as
observed in NHR, appears to be rather high and is presum-
ably not solely explicable by individual clinical situations.
The data further show that the average number of drug
prescriptions per patient in Swiss nursing homes is rather
high. However, we need to interpret these data carefully, as
dermatological products for dry skin, artificial tears, calci-
um supplements or Vitamin D3 are also part of this assess-
ment. Thus, whether the average number of drugs applied
to NHR is indeed problematic or not needs to be interpret-
ed in the context of the clinical situation. However, these
findings are nevertheless in line with a growing body of
evidence indicating the need to focus on drug safety, to im-
prove prescribing practices and to prescribe as few drugs
as absolutely necessary in the elderly [17, 20–22, 35].
Future national policies might aim at promoting rational
drug use in geriatric patients. One possible approach is
based on defining a responsible clinical pharmacist for
every nursing home and on close interdisciplinary collab-
oration between healthcare providers in the nursing home
setting. This approach has already been successfully tested
at a cantonal level [36] and might be a promising approach
for future interventions aimed to increase efficacy and
quality of drug prescriptions in NHR.
To ensure transparent prescription practice, it is essential
for all health professionals involved in the treatment of
NHR to share information. Pharmacists have the oppor-
tunity to identify PIM or drugs with interaction potential
before they reach the patient; physicians may gain an
overview of the drugs used by consulting PIM criteria and
have the opportunity to inform NHR about benefits and
risks of a therapy; nursing professionals who personally
know the NHR and administer drugs to them on a dai-
ly basis can make an important contribution by provid-
ing feedback to the other professional groups. In addition,
the patients’ and relatives’ problem-awareness should be
sharpened to develop an understanding that reducing the
number of drugs is not necessarily associated with a reduc-
tion in performance, but may lead to a reduction of risks.
In conclusion, this study provides a comprehensive evalu-
ation of drug utilisation in Swiss nursing homes. The re-
sults show that polypharmacy and use of PIM are frequent
in NHR. Even though the absolute number of drugs is per
se not a meaningful indicator of high or poor prescribing
quality, we need to keep in mind that both polypharmacy
and PIM are potentially problematic and may be associat-
ed with poor health outcomes in elderly people. The data
further show that innovative high-cost drugs introduced in
oncology, immunology and infectiology are rarely used in
the nursing home setting. This results in average drug costs
of only around CHF 8 per day for NHR, so that drug costs
constitute a minor part of the total healthcare costs of pa-
tients in nursing homes. The present study quantifies drug
utilisation of NHR and may indicate a need for effective
interventions to optimise drug prescribing in Swiss nursing
homes.
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